
    
      This is a single-center, prospective randomized open or non-blinded end-point (PROBE)
      clinical trial. Patients will be selected by the neurosurgeon according to the inclusion and
      exclusion criteria. Patients who consent to randomization will have confirmed non-eloquent
      status confirmed by independent surgeon and will be randomized into 1 of 2 treatment groups
      utilizing a dynamic minimization approach. The experimental group with randomization of
      patients who will undergo awake craniotomy for both high and low grade gliomas in
      non-eloquent areas or a control group of patients who will have asleep craniotomy for both
      high and low grade gliomas in non-eloquent regions.
    
  